MAYBE CHARGING CONSUMERS THE LOW PRICE of $599 for a whole human genome sequence is not a winning financial strategy. That’s one possible reason why closely-watched Veritas Genetics of Cambridge, Mass., will stop operations in the United States.
It was in July that Veritas announced it was cutting its already-low price to sequence a genome from
CEO SUMMARY: It’s a case of the little fish gobbling the big fish, as Opko Health—with revenue of $91 million—will be acquiring Bio-Reference Laboratories, with revenue of $832 million. But the more interesting aspect of the story is that the CEO of Opko Health is a physician worth $5 billion and highly respected by Wall Street. It could be that Bio-Reference CEO Marc Grodman, M.D., has gained a shrewd advisor and powerful ally in Phillip Frost, M.D., the Chair and CEO of Opko Health.
EVERY DAY, ACROSS THE GLOBE, labs perform testing using Sanger sequencing and other fundamental techniques of proteomics and genomics pioneered and developed by Frederick Sanger, who died last month at the age of 95.
Sanger is considered one of the giants in biochemistry. He was one of only three people awarded two Nobel prizes in science.
Even as the cost of genetic sequencing falls, the number of gene profiles in data repositories increases. This month, a research project in Boston, Massachusetts, that includes Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Boston Children’s Hospital reported that it now has over 5,000 genetic profiles of tumor DNA in its database. The project
Earlier this month, the clinical laboratory at Ohio State University Wexner Medical Center (OSUWMC) was sent a letter by federal CLIA (Clinical Laboratory Improvement Act) officials declaring that the laboratory was in violation of proficiency testing (PT) regulations. The OSUWMC laboratory faces two sanctions. One is revocation of its CLIA license. The second is cancellation
It’s a milestone on the path to personalized medicine and an example of how integrated health informatics will give clinicians real-time access to unlimited amounts of medical data. The 1000 Genomes Project announced in recent months that “the world’s largest set of data on human variation” is now available on the Amazon Web Services cloud
CEO SUMMARY: Once again, Roche is hunting for gene sequencing and gene analysis technology that can support its goal of being a world leader in gene-based therapeutics and clinical lab testing that utilizes gene tests and molecular diagnostics. Last week, Roche launched a hostile stock tender offer for shares of Illumina, Inc., of San Diego,
CEO SUMMARY: There’s been an uneasy standoff between companies that want to sell genetic tests directly to consumers over the Internet and both state and federal regulators. But now it appears that the FDA is ready to take off the gloves and assert greater control over genetic testing. The agency moved swiftly to challenge six
CEO SUMMARY: PerkinElmer’s interest in the multiplex capabilities of Luminex’s xMap technology led to this new licensing agreement. PerkinElmer’s instrument systems played a major role in accelerating the work of the Human Genome Project. Now, besides bioresearch applications, PerkinElmer wants to look for opportunities to develop high-volume, multi-analyte assays for in vitro diagnostics.